Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Technological advances have made the artificial pancreas a reality. This has the potential to improve the lives of individuals with Type 1 diabetes by reducing the risk of hypoglycaemia, achieving better overall glucose control, and enhancing quality of life. Both single‐hormone (insulin‐only) and dual‐hormone (insulin and glucagon) systems have been developed; however, a focused review of the relative benefits of each artificial pancreas system is needed. We reviewed studies that directly compared single‐ and dual‐hormone systems to evaluate the efficacy of each system for preventing hypoglycaemia and maintaining glycaemic control, as well as their utility in specific situations including during exercise, overnight and during the prandial period. We observed additional benefits with the dual‐hormone artificial pancreas for reducing the risk of hypoglycaemic events overall and during exercise over the study duration. The single‐hormone artificial pancreas was sufficient for maintenance of euglycaemia in the overnight period and for preventing late‐onset post‐exercise hypoglycaemia. Future comparative studies of longer duration are required to determine whether one system is superior for improving mean glucose control, eliminating severe hypoglycaemia, or improving quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Exercise-stimulated glucose uptake — regulation and implications for glycaemic control
Sylow, L., Kleinert, M., Richter, E. A., & Jensen, T. E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.162 · Cited by 498
Cappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
Glucagon and plasma catecholamine responses to graded and prolonged exercise in man
Galbo, H., Holst, J. J., & Christensen, N. J. (1975) · Journal of Applied Physiology · doi:10.1152/jappl.1975.38.1.70 · Cited by 406
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Home, P. D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01580.x · Cited by 212
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Haidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
Self-citationSherr, J. L., Cengiz, E., Palerm, C. C., Clark, B., Kurtz, N., Roy, A., Carria, L., Cantwell, M., Tamborlane, W. V., & Weinzimer, S. A. (2013) · Diabetes Care · doi:10.2337/dc13-0010 · Cited by 125
Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
Siafarikas, A., Johnston, R. J., Bulsara, M. K., O’Leary, P., Jones, T. W., & Davis, E. A. (2012) · Diabetes Care · doi:10.2337/dc11-2010 · Cited by 120
Jacobs, P. G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12707 · Cited by 116
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
Renard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39
Ward, W. K., Castle, J. R., & Youssef, J. E. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500608 · Cited by 36
Fast-acting insulin aspart: the rationale for a new mealtime insulin
Evans, M., Wilkinson, M., & Giannpolou, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00685-0 · Cited by 23
Cited by
Cappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
A Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control
Kovatchev, B. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.008 · Cited by 80
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
Fast-acting insulin aspart: the rationale for a new mealtime insulin
Evans, M., Wilkinson, M., & Giannpolou, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00685-0 · Cited by 23
“The use of glucagon in dual hormone systems (glucagon and insulin) may mitigate the risk for hypoglycaemia and improve glucose control [31].”
Background
Metadata
- Authors
- Peters, T. M., & Haidar, A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2018-02-11
- Volume
- 35
- Issue
- 4
- Pages
- 450-459
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2783274781
- Cited by
- 71
- References
- 23
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.